Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 21, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Sangamo Therapeutics, Inc. (SGMO) has a Wall Street consensus price target of $7.25, based on estimates from 14 covering analysts. With the stock currently trading at $0.43, this represents a potential upside of +1577.1%. The company has a market capitalization of $92M.
Analyst price targets range from a low of $2.00 to a high of $19.00, representing a 234% spread in expectations. The median target of $4.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 6 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SGMO trades at a trailing P/E of -0.9x. Analysts expect EPS to grow +31.8% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SGMO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for SGMO is $7.25, representing 1577.1% upside from the current price of $0.4323. With 14 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SGMO has a consensus rating of "Hold" based on 14 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $7.25 implies 1577.1% upside from current levels.
SGMO's current price is $0.4323 with a consensus target of $7.25 (1577.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $19 for SGMO, while the most conservative target is $2. The consensus of $7.25 represents the median expectation. These targets typically reflect 12-month expectations.
SGMO is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 7 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SGMO stock forecast based on 14 Wall Street analysts shows a consensus price target of $7.25, with estimates ranging from $2 (bear case) to $19 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on SGMO, with a "Hold" consensus rating and $7.25 price target (1577.1% upside). 6 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SGMO analyst price targets range from $2 to $19, a 234% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7.25 consensus represents the middle ground.